NCT06141369 — Shanghai Jiao Tong University School of… neoantigen vaccine trial
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Registry record
| Registry ID | NCT06141369 ↗ |
|---|---|
| Lead sponsor | Shanghai Jiao Tong University School of Medicine |
| Collaborators | — |
| Phase | Phase NA |
| Status | Recruiting |
| Indication | Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor |
| Enrollment | 21 participants (target) |
| Start date | 2024-01-13 |
| Primary completion | 2026-12-30 (est.) |
| Last registry update | 9 Apr 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06141369), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT06141369?
NCT06141369 (Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)) is registered on ClinicalTrials.gov as Phase NA, sponsored by Shanghai Jiao Tong University School of Medicine.
Is NCT06141369 recruiting?
As of the 2026-04-09 registry update, NCT06141369 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06141369?
The lead sponsor is Shanghai Jiao Tong University School of Medicine.
What condition does NCT06141369 study?
The registered conditions are Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor. Primary completion is listed as 2026-12-30 (estimated).
Are results available for NCT06141369?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06141369.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.